An Open-label, Long Term Extension Study of MT-8554 in Postmenopausal Women Experiencing Moderate to Severe Vasomotor Symptoms Who Completed Study MT-8554-A01
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Elismetrep (Primary)
- Indications Vasomotor symptoms
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 12 May 2019 Planned End Date changed from 1 Jul 2019 to 1 Mar 2020.
- 12 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Dec 2019.
- 25 Oct 2018 Status changed from recruiting to active, no longer recruiting.